Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. International most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2018;68(6):394–424.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6.
Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a part III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in sufferers with superior hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66.
Kudo M, Finn RS, Qin S, Han KH, Ikeda Ok, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line therapy of sufferers with unresectable hepatocellular carcinoma: a randomised part 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
Zupancic S, Lavric Z, Kristl J. Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature. Eur J Pharm Biopharm. 2015;93:196–204.
Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, et al. Chinese language natural medicine-derived compounds for most cancers remedy: a deal with hepatocellular carcinoma. J Ethnopharmacol. 2013;149(3):601–12.
Cheng Y, Zhao P, Wu S, Yang T, Chen Y, Zhang X, et al. Cisplatin and curcumin co-loaded nano-liposomes for the therapy of hepatocellular carcinoma. Int J Pharm. 2018;545(1–2):261–73.
Najafi M, Mortezaee Ok, Rahimifard M, Farhood B, Haghi-Aminjan H. The function of curcumin/curcuminoids throughout gastric most cancers chemotherapy: a scientific assessment of non-clinical examine. Life Sci. 2020;257: 118051.
Ramezani Farani M, Azarian M, Heydari Sheikh Hossein H, Abdolvahabi Z, Mohammadi Abgarmi Z, Moradi A, et al. Folic acid-adorned curcumin-loaded iron oxide nanoparticles for cervical most cancers. ACS Appl Bio Mater. 2022;5(3):1305–18.
Li J, Wei H, Liu Y, Li Q, Guo H, Guo Y, et al. Curcumin inhibits hepatocellular carcinoma by way of regulating miR-21/TIMP3 axis. Evid Primarily based Complement Altern Med. 2020;2020:2892917.
Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver most cancers: a assessment. Curr Pharm Biotechnol. 2012;13(1):218–28.
Xue YQ, Di JM, Luo Y, Cheng KJ, Wei X, Shi Z. Resveratrol oligomers for the prevention and therapy of cancers. Oxid Med Cell Longev. 2014;2014: 765832.
Amini P, Nodooshan SJ, Ashrafizadeh M, Eftekhari SM, Aryafar T, Khalafi L, et al. Resveratrol induces apoptosis and attenuates proliferation of MCF-7 cells together with radiation and hyperthermia. Curr Mol Med. 2021;21(2):142–50.
Vernousfaderani EK, Akhtari N, Rezaei S, Rezaee Y, Shiranirad S, Mashhadi M, et al. Resveratrol and colorectal most cancers: a molecular strategy to medical researches. Curr High Med Chem. 2021;21(29):2634–46.
Qian W, Xiao Q, Wang L, Qin T, Xiao Y, Li J, et al. Resveratrol slows the tumourigenesis of pancreatic most cancers by inhibiting NFkappaB activation. Biomed Pharmacother. 2020;127:110116.
Zaffaroni N, Beretta GL. Resveratrol and prostate most cancers: the facility of phytochemicals. Curr Med Chem. 2021;28(24):4845–62.
Tune F, Zhang Y, Pan Z, Zhang Q, Lu X, Huang P. Resveratrol inhibits the migration, invasion and epithelial-mesenchymal transition in liver most cancers cells by up- miR-186–5p expression. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50(5):582–90.
Kohandel Z, Farkhondeh T, Aschner M, Pourbagher-Shahri AM, Samarghandian S. STAT3 pathway as a molecular goal for resveratrol in breast most cancers therapy. Most cancers Cell Int. 2021;21(1):468.
Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a assessment. Crit Rev Meals Sci Nutr. 2018;58(9):1428–47.
Cheuk IW, Chen J, Siu M, Ho JC, Lam SS, Shin VY, et al. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast most cancers. Clin Transl Oncol. 2022;24(5):854–63.
Bostan M, Mihaila M, Petrica-Matei GG, Radu N, Hainarosie R, Stefanescu CD, et al. Resveratrol modulation of apoptosis and cell cycle response to cisplatin in head and neck most cancers cell traces. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22126322.
Abadi AJ, Mirzaei S, Mahabady MK, Hashemi F, Zabolian A, Hashemi F, et al. Curcumin and its derivatives in most cancers remedy: potentiating antitumor exercise of cisplatin and decreasing negative effects. Phytother Res. 2022;36(1):189–213.
Muhanmode Y, Wen MK, Maitinuri A, Shen G. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian most cancers cells by way of concentrating on P13K pathway. Hum Exp Toxicol. 2021;40(12_suppl):S861–8.
Guo W, Wu X, Li Y, Gao J, Wang F, Jin Y, et al. Analysis of biophysical in addition to biochemical potential of curcumin and resveratrol throughout prostate most cancers. J Drug Goal. 2020;28(1):41–5.
Carlson LJ, Cote B, Alani AW, Rao DA. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci. 2014;103(8):2315–22.
Area A, Romeo MA, Benedetti R, Masuelli L, Bei R, Gilardini Montani MS, et al. New Insights into curcumin- and resveratrol-mediated anti-cancer results. Prescribed drugs. 2021. https://doi.org/10.3390/ph14111068.
Patra S, Pradhan B, Nayak R, Behera C, Rout L, Jena M, et al. Chemotherapeutic efficacy of curcumin and resveratrol in opposition to most cancers: Chemoprevention, chemoprotection, drug synergism and medical pharmacokinetics. Semin Most cancers Biol. 2021;73:310–20.
Meng L, Chu X, Xing H, Liu X, Xin X, Chen L, et al. Enhancing glioblastoma therapeutic outcomes by way of doxorubicin-loaded nanomicelles modified with borneol. Int J Pharm. 2019;567: 118485.
Huang X, Li M, Bruni R, Messa P, Cellesi F. The impact of thermosensitive liposomal formulations on loading and launch of excessive molecular weight biomolecules. Int J Pharm. 2017;524(1–2):279–89.
Li R, He Y, Zhang S, Qin J, Wang J. Cell membrane-based nanoparticles: a brand new biomimetic platform for tumor analysis and therapy. Acta Pharmaceut Sin B. 2018;8(1):14–22.
Liu W, Wei F, Ye A, Tian M, Han J. Kinetic stability and membrane construction of liposomes throughout in vitro toddler intestinal digestion: impact of ldl cholesterol and lactoferrin. Meals Chem. 2017;230:6–13.
Reddy BP, Yadav HK, Nagesha DK, Raizaday A, Karim A. Polymeric micelles as novel carriers for poorly soluble medicine–a assessment. J Nanosci Nanotechnol. 2015;15(6):4009–18.
de Ghellinck A, Shen C, Fragneto G, Klosgen B. Probing the place of resveratrol in lipid bilayers: a neutron reflectivity examine. Colloids Surf B. 2015;134:65–72.
Karewicz A, Bielska D, Gzyl-Malcher B, Kepczynski M, Lach R, Nowakowska M. Interplay of curcumin with lipid monolayers and liposomal bilayers. Colloids Surf B. 2011;88(1):231–9.
Wang H, Xie H, Wu J, Wei X, Zhou L, Xu X, et al. Construction-based rational design of prodrugs to allow their mixture with polymeric nanoparticle supply platforms for enhanced antitumor efficacy. Angew Chem. 2014;53(43):11532–7.
Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Focusing on the transferrin receptor for mind drug supply. Prog Neurobiol. 2019;181: 101665.
Rastegar R, Akbari Javar H, Khoobi M, Dehghan Kelishadi P, Hossein Yousefi G, Doosti M, et al. Analysis of a novel biocompatible magnetic nanomedicine primarily based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast most cancers. Artif Cells Nanomed Biotechnol. 2018;46(sup2):207–16.
Yang Z, Liu J, Lu Y. Doxorubicin and CDCUR inclusion complicated coloaded in thermosensitive hydrogel PLGAPEGPLGA localized administration for osteosarcoma. Int J Oncol. 2020;57(2):433–44.
Rafati N, Zarrabi A, Caldera F, Trotta F, Ghias N. Pyromellitic dianhydride crosslinked cyclodextrin nanosponges for curcumin managed launch; formulation, physicochemical characterization and cytotoxicity investigations. J Microencapsul. 2019;36(8):715–27.
Yang Z, Wang J, Liu S, Li X, Miao L, Yang B, et al. Defeating relapsed and refractory malignancies by a nano-enabled mitochondria-mediated respiratory inhibition and injury pathway. Biomaterials. 2020;229: 119580.
Li Y, Hu Y, Xiao J, Liu G, Li X, Zhao Y, et al. Investigation of SP94 peptide as a selected probe for hepatocellular carcinoma imaging and remedy. Sci Rep. 2016;6:33511.
Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The focused supply of multicomponent cargos to most cancers cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389–97.
Toita R, Murata M, Tabata S, Abe Ok, Narahara S, Piao JS, et al. Improvement of human hepatocellular carcinoma cell-targeted protein cages. Bioconjug Chem. 2012;23(7):1494–501.
Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: doable targets and future instructions. Nat Rev Clin Oncol. 2011;8(5):292–301.
Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging research of hybrid paclitaxel nanocrystals: classes discovered of the EPR impact and image-guided drug supply. J Management Launch. 2013;172(1):12–21.
Khan H, Ullah H, Nabavi SM. Mechanistic insights of hepatoprotective results of curcumin: therapeutic updates and future prospects. Meals Chem Toxicol. 2019;124:182–91.
Circu ML, Aw TY. Reactive oxygen species, mobile redox programs, and apoptosis. Free Radical Biol Med. 2010;48(6):749–62.
Bishayee A, Politis T, Darvesh AS. Resveratrol within the chemoprevention and therapy of hepatocellular carcinoma. Most cancers Deal with Rev. 2010;36(1):43–53.
Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini A, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance by inhibition of caspase-3-mediated apoptosis. Clin Most cancers Res. 2017;23(14):3953–65.
Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, et al. A hepatocellular carcinoma concentrating on nanostrategy with hypoxia-ameliorating and photothermal talents that, mixed with immunotherapy, inhibits metastasis and recurrence. ACS Nano. 2020;14(10):12679–96.
Chou T-C, Martin N. CompuSyn software program for drug combos and for basic dose-effect evaluation, and consumer’s information. Paramus: ComboSyn, Inc.; 2007.
Cote B, Carlson LJ, Rao DA, Alani AWG. Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo. J Management Launch. 2015;213:128–33.
Pedre B, Barayeu U, Ezerina D, Dick TP. The mechanism of motion of N-acetylcysteine (NAC): the rising function of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228: 107916.
Zhu L, Yuan H, Guo C, Lu Y, Deng S, Yang Y, et al. Zearalenone induces apoptosis and necrosis in porcine granulosa cells by way of a caspase-3- and caspase-9-dependent mitochondrial signaling pathway. J Cell Physiol. 2012;227(5):1814–20.
Zhang C, Xin L, Li J, Cao J, Solar Y, Wang X, et al. Metallic-organic framework (MOF)-based ultrasound-responsive dual-sonosensitizer nanoplatform for hypoxic most cancers remedy. Adv Healthc Mater. 2022;11(2): e2101946.